Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4,4'-(1h-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
2. Cgs 20267
3. Cgs-20267
4. Cgs20267
5. Fmara
6. Femara
1. 112809-51-5
2. Femara
3. 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4. Letrozol
5. Cgs 20267
6. Cgs-20267
7. 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
8. 4,4'-(1h-1,2,4-triazol-1-ylmethylene)dibenzonitrile
9. Letrazole
10. Benzonitrile, 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-
11. Femera
12. 4,4'-(1h-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
13. 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
14. Nsc-759652
15. Chembl1444
16. 4-[(4-cyanophenyl)(1h-1,2,4-triazol-1-yl)methyl]benzonitrile
17. 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
18. 7lkk855w8i
19. Chebi:6413
20. 4,4'-(1h-1,2,4-triazol-1-ylmethylene) Bis-benzonitrile
21. Ncgc00016973-01
22. Letoval
23. Cas-112809-51-5
24. Dsstox_cid_3202
25. Dsstox_rid_76924
26. Dsstox_gsid_23202
27. Smr000466343
28. Femara (tn)
29. Hsdb 7461
30. Sr-01000759382
31. Letrozole (jan/usp/inn)
32. Unii-7lkk855w8i
33. Ccris 8822
34. 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
35. Fem-345
36. Femara, Letrozole
37. Letrozole [usan:usp:inn:ban]
38. Letrozole- Bio-x
39. Cgs20267
40. Mfcd00866241
41. Letrozole [inn]
42. Letrozole [jan]
43. Letrozole [mi]
44. Letrozole [hsdb]
45. Letrozole [usan]
46. Prestwick0_001025
47. Prestwick1_001025
48. Prestwick2_001025
49. Prestwick3_001025
50. Femara (tn) (novartis)
51. Letrozole [mart.]
52. Letrozole [usp-rs]
53. Letrozole [who-dd]
54. Schembl4331
55. 1-[bis-(4-cyanophenyl)methyl]-1,2,4-triazole
56. Bidd:pxr0130
57. Bspbio_001209
58. Mls000759455
59. Mls001424038
60. Mls002584991
61. Mls006010040
62. Bidd:gt0015
63. Spbio_003070
64. Bpbio1_001331
65. Gtpl5209
66. Letrozole [ep Impurity]
67. Letrozole [orange Book]
68. Dtxsid4023202
69. Letrozole [ep Monograph]
70. Letrozole, >=98% (hplc)
71. Bdbm13061
72. Ex-a965
73. Letrozole [usp Monograph]
74. Hms1571m11
75. Hms2051e08
76. Hms2089l22
77. Hms2098m11
78. Hms2233c23
79. Hms3369e11
80. Hms3393e08
81. Hms3651k05
82. Hms3715m11
83. Pharmakon1600-01502354
84. Amy32541
85. Bcp23354
86. Zinc3778874
87. Tox21_110719
88. Tox21_303572
89. Nsc719345
90. Nsc759652
91. S1235
92. Stl451047
93. Akos005145822
94. Ab07525
95. Ac-1193
96. Bcp9000848
97. Ccg-100849
98. Cs-1776
99. Db01006
100. Ks-1269
101. Nc00099
102. Nsc 759652
103. Nsc-719345
104. Ncgc00016973-02
105. Ncgc00016973-03
106. Ncgc00016973-06
107. Ncgc00257460-01
108. Bl164620
109. Hy-14248
110. Bcp0726000213
111. 1-bis(4-cyanophenyl)methyl-1,2,4-triazole
112. 4,2,4-triazol-1-ylmethylene)dibenzonitrile
113. Ab00514009
114. L0248
115. Sw197294-4
116. A25380
117. C08163
118. D00964
119. Ab00514009-05
120. Ab00514009-07
121. Ab00514009-08
122. Ab00514009-09
123. Ab00514009_10
124. Ab00514009_11
125. 809l515
126. Kisqali Femara Co-pack Component Letrozole
127. Q194974
128. W-60273
129. 4,4'-(1,2,4-triazol-1-ylmethylene)dibenzonitrile
130. Letrozole Component Of Kisqali Femara Co-pack
131. Q-201291
132. Sr-01000759382-4
133. Sr-01000759382-5
134. Brd-k88789588-001-03-2
135. 4,4 -(1h-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
136. 4,4'-(1h-1,2,4-triazol-1-ylmethylene)-bisbenzonitrile
137. F2173-0288
138. Z1741968261
139. 4,4'-((1h-1,2,4-triazol-1-yl)-methylene)dibenzonitrile
140. Letrozole, European Pharmacopoeia (ep) Reference Standard
141. Letrozole, United States Pharmacopeia (usp) Reference Standard
142. 4-[1-(4-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile
143. Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material
Molecular Weight | 285.30 g/mol |
---|---|
Molecular Formula | C17H11N5 |
XLogP3 | 2.7 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 285.10144537 g/mol |
Monoisotopic Mass | 285.10144537 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 420 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Femara |
PubMed Health | Letrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Femara tablets for oral administration contains 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, and its structural formula i |
Active Ingredient | Letrozole |
Dosage Form | Tablet |
Route | Oral |
Strength | 2.5mg |
Market Status | Prescription |
Company | Novartis Pharms |
2 of 4 | |
---|---|
Drug Name | Letrozole |
PubMed Health | Letrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Letrozole tablets USP for oral administration contain 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-triazol-1-ylmethylene)dibenzonitrile, and its structural for |
Active Ingredient | Letrozole |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 2.5mg |
Market Status | Tentative Approval; Prescription |
Company | Vintage Pharms; Fresenius Kabi Oncol; Apotex; Accord Hlthcare; Jiangsu Hengrui Med; Indicus Pharma; Natco Pharma; Sun Pharm Inds; Roxane; Teva Pharms; Kudco Ireland; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs |
3 of 4 | |
---|---|
Drug Name | Femara |
PubMed Health | Letrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Femara tablets for oral administration contains 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, and its structural formula i |
Active Ingredient | Letrozole |
Dosage Form | Tablet |
Route | Oral |
Strength | 2.5mg |
Market Status | Prescription |
Company | Novartis Pharms |
4 of 4 | |
---|---|
Drug Name | Letrozole |
PubMed Health | Letrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Letrozole tablets USP for oral administration contain 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-triazol-1-ylmethylene)dibenzonitrile, and its structural for |
Active Ingredient | Letrozole |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 2.5mg |
Market Status | Tentative Approval; Prescription |
Company | Vintage Pharms; Fresenius Kabi Oncol; Apotex; Accord Hlthcare; Jiangsu Hengrui Med; Indicus Pharma; Natco Pharma; Sun Pharm Inds; Roxane; Teva Pharms; Kudco Ireland; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs |
Antineoplastic
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 974
Letrozole is indicated for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Letrozole is also indicated for treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1902
A 37-year-old premenopausal woman with relapsed breast cancer (BC) in the right supraclavicular nodes, after failed treatment with the combination luteinizing hormone releasing hormone-a (LHRHa; triptorelin) plus tamoxifen, was started on triptorelin 3.75 mg every 28 days plus letrozole 2.5 mg daily. Approximately 6 months after starting this therapy, she complained of a daily scalp hair loss while combing and progressively developed a diffuse non-scarring alopecia on her crown. There were no signs of virilization ... She was not taking any other drug. Hematological parameters were normal. Blood examination ruled out pituitary or thyroid problems. There were no other possible causes that could induce alopecia, such as lupus erythematosus, HIV infection, secondary syphilis, or deficiencies of protein, iron, biotin or zinc.
PMID:14581280 Carlini P et al; Ann Oncol 14 (11): 1689-90 (2003)
In patients receiving letrozole as first-line therapy, bone pain, back pain, and limb pain occurred in 22, 18, and 10% of patients, respectively. In patients receiving letrozole as second-line therapy, adverse musculoskeletal effects (including musculoskeletal pain, skeletal pain, back pain, arm pain, and leg pain) were reported in 21% and fracture was reported in less than 5% of patients. Arthralgia was reported in 16% of patients receiving letrozole as first-line therapy and in 8% of patients receiving the drug as second-line therapy. Hypercalcemia occurred in less than 5% of patients receiving letrozole as second-line therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1114
Adverse musculoskeletal effects have been reported in patients receiving letrozole as adjuvant therapy for early-stage breast cancer in clinical trials. In a double-blind, randomized trial in postmenopausal women with hormone receptor-positive breast cancer who had received approximately 5 years of tamoxifen adjuvant therapy following primary treatment for early breast cancer, extended adjuvant therapy with letrozole was associated with an increased incidence of arthritis, arthralgia, and myalgia, and a trend toward higher rates of newly diagnosed osteoporosis and bone fracture compared with placebo therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1114
All women receiving adjuvant therapy with letrozole should be advised to adopt lifestyle changes (eg, weight-bearing exercise, abstinence from smoking, moderation in alcohol consumption) and dietary supplementation with calcium and vitamin D to reduce the risk of osteoporosis.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1114
For more Drug Warnings (Complete) data for LETROZOLE (26 total), please visit the HSDB record page.
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
FDA Label
Letrozole is an aromatase inhibitor used in the treatment of breast cancer. Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue. Letrozole is a third generation type II aromatase inhibitor used to treat estrogen dependant breast cancers. It has a long duration of action as it has a half life of over 42 hours in breast cancer patients. Patients should be counselled regarding the risk of interstitial lung disease, pneumonitis, QT prolongation, elevated transaminase levels, neutropenia, and embryo-fetal toxicity.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Aromatase Inhibitors
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (See all compounds classified as Aromatase Inhibitors.)
L02BG04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02B - Hormone antagonists and related agents
L02BG - Aromatase inhibitors
L02BG04 - Letrozole
Absorption
Letrozole is 99.9% orally bioavailable. A 2.5mg oral dose reaches a Cmax of 104nmol/L with a Tmax of 8.10h, and an AUC of 7387nmol\*h/L.
Route of Elimination
Letrozole is 90% eliminated in the urine. 75% of the dose is recovered as a glucuronide metabolite, 9% is in the form of the ketone and carbinol metabolites, and 6% is recovered in urine as unchanged letrozole.
Volume of Distribution
The volume of distribution of letrozole is 1.87L/kg.
Clearance
The average clearance after a single dose of letrozole was 1.52L/h and at steady state was 1.20L/h.
Letrozole is rapidly and completely absorbed from the GI tract following oral administration. Steady-state plasma concentrations of the drug are reached in 2-6 weeks in patients receiving letrozole 2.5 mg daily. Letrozole exhibits slightly nonlinear pharmacokinetics with repeated administration of 2.5 mg daily, with steady-state plasma concentrations 1.5-2 times higher than predicted based on plasma concentrations measured after a single dose. However, continuous accumulation of letrozole does not occur, and steady-state concentrations are maintained over extended periods of daily drug administration. Food does not affect the oral absorption of the drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1116
Letrozole has a large volume of distribution of approximately 1.9 L/kg. Letrozole is weakly bound to plasma proteins.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1116
Following oral administration of radiolabeled letrozole, 90% of the administered dose was excreted in the urine. Of the radiolabeled drug recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% consisted of 2 unidentified metabolites, and 6% was unchanged drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1116
It is not known whether letrozole is distributed into human breast milk.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 1902
For more Absorption, Distribution and Excretion (Complete) data for LETROZOLE (6 total), please visit the HSDB record page.
Letrozole is metabolized by CYP2A6 to a ketone analog metabolite, which is further metabolized by CYP3A4 and CYP2A6 to 4,4'-(hydroxymethylene)dibenzonitrile. 4,4'-(hydroxymethylene)dibenzonitrile is glucuronidated by UGT2B7.
The primary elimination pathway of letrozole consists of slow metabolism in the liver to a pharmacologically inactive carbinol metabolite (4,4'-methanol-bisbenzonitrile) followed by renal excretion of the glucuronide conjugate of this metabolite. Formation of the carbinol metabolite is mediated by cytochrome P-450 (CYP) isoenzymes 3A4 and 2A6, and formation of the ketone analog of the carbinol metabolite is mediated by isoenzyme 2A6.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1116
The terminal elimination half life of letrozole is approximately 42h in healthy volunteers, but longer in breast cancer patients.
Letrozole has a terminal elimination half-life of about 2 days.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 1116
Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone. In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels.
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.
Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 2210
GDUFA
DMF Review : Complete
Rev. Date : 2020-08-18
Pay. Date : 2020-08-12
DMF Number : 21182
Submission : 2007-12-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20566
Submission : 2007-05-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19170
Submission : 2006-02-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20175
Submission : 2008-06-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-02-23
Pay. Date : 2018-02-12
DMF Number : 18388
Submission : 2005-06-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19622
Submission : 2006-07-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20020
Submission : 2006-12-09
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-02
Pay. Date : 2013-06-20
DMF Number : 19139
Submission : 2006-01-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20761
Submission : 2007-07-30
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-08
Pay. Date : 2012-12-18
DMF Number : 20356
Submission : 2007-03-07
Status : Active
Type : II
Certificate Number : CEP 2022-209 - Rev 00
Status : Valid
Issue Date : 2024-03-18
Type : Chemical
Substance Number : 2334
Certificate Number : R0-CEP 2011-066 - Rev 00
Status : Expired
Issue Date : 2013-05-24
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2010-300 - Rev 00
Status : Valid
Issue Date : 2019-07-08
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2012-350 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2022-06-22
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2007-150 - Rev 03
Status : Valid
Issue Date : 2017-02-14
Type : Chemical
Substance Number : 2334
Certificate Number : R0-CEP 2019-149 - Rev 00
Status : Valid
Issue Date : 2020-09-03
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2013-321 - Rev 01
Status : Valid
Issue Date : 2022-07-20
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2009-147 - Rev 01
Status : Valid
Issue Date : 2022-03-08
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2013-214 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2019-10-01
Type : Chemical
Substance Number : 2334
Certificate Number : R1-CEP 2008-280 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2015-04-30
Type : Chemical
Substance Number : 2334
Registration Number : 226MF10028
Registrant's Address : 7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana I...
Initial Date of Registration : 2014-02-05
Latest Date of Registration : 2014-02-05
Registration Number : 226MF10023
Registrant's Address : Village-Bhagwanpur, Barwala Road, Derabassi-140 507 District-S. A. S. Nagar (Mohali)P...
Initial Date of Registration : 2014-01-21
Latest Date of Registration : 2014-11-17
Registration Number : 226MF10030
Registrant's Address : No. 7, Kunlunshan Road, Economic and Technological Development Zone, Lianyungang, Jia...
Initial Date of Registration : 2014-02-05
Latest Date of Registration : 2014-02-05
Registration Number : 226MF10005
Registrant's Address : Natco House, Road No. 2, Banjara Hills,Hyderabad 500034, Telangana, India
Initial Date of Registration : 2014-01-08
Latest Date of Registration : 2014-11-17
Registration Number : 226MF10063
Registrant's Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
Initial Date of Registration : 2014-03-06
Latest Date of Registration : 2024-05-08
Registration Number : 226MF10029
Registrant's Address : Shilpa House, #12-6-214/A1, Hyderabad Road, Raichur-584 135, Karnataka, India
Initial Date of Registration : 2014-02-05
Latest Date of Registration : 2015-04-21
Registration Number : 306MF10027
Registrant's Address : Plot No. 290, Srivalli's Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad-5...
Initial Date of Registration : 2024-02-14
Latest Date of Registration : 2024-02-14
Registration Number : 226MF10041
Registrant's Address : 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, Andhra Pradesh, India
Initial Date of Registration : 2014-02-19
Latest Date of Registration : 2014-02-19
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operations Unit-VI, APIIC Industrial Estate, Pydibhimavaram V...
Date of Issue : 2022-11-09
Valid Till : 2025-08-08
Written Confirmation Number : WC-0138
Address of the Firm : Plot No. 285, 286 & 287, Bommasandra-Jigani Link Road, Industrial Area, KIADB, 4...
Date of Issue : 2019-07-08
Valid Till : 2022-07-07
Written Confirmation Number : WC-0115
Address of the Firm : D-35, Industrial Area, Kalyani, Dist Nadia-741 235, West Bengal
Date of Issue : 2022-09-16
Valid Till : 2025-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Survey No.10, I.D.A, Gaddapotharam Village, Jinnaram Mandal,Medak Dist, ...
Date of Issue : 2022-06-03
Valid Till : 2025-05-27
Written Confirmation Number : WC-0003
Address of the Firm : Vill.- Bhagwanpur, Barwala Road, Near Dera Bassi, Distt.- SAS Nagar (Mohali), Pu...
Date of Issue : 2021-01-22
Valid Till : 2023-08-01
Written Confirmation Number : WC-0275
Address of the Firm : N-211/2/10, MIDC, Boisar, Dist-Thane-401506, Mahrashtra
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0014
Address of the Firm : Mekaguda (V) kothur (M) Mahabood nagar Dist, Telangana State India
Date of Issue : 2019-07-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0147
Address of the Firm : 100% EOU, Raichur Industrial Growth Centre, Plot No. 33, 33A, 40-47, Chicksugur-...
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm : A-7/A-8, MIDC, Ahmednagar-414 111, Maharashtra State
Date of Issue : 2019-10-11
Valid Till : 2022-07-02
Written Confirmation Number : WC-0157
Address of the Firm : Plot No. 1A/2, MIDC, Taloja, Panvel, Dist. Raigad, Maharashtra State
Registrant Name : Novartis Korea Ltd.
Registration Date : 2021-09-10
Registration Number : 20210910-209-J-1104
Manufacturer Name : FINORGA SAS@Jetpharma SA
Manufacturer Address : route de Givors Chasse Sur Rhone,38670, France@Via Sottobisio 42A, 6828 Balerna,Switz...
Registrant Name : Shin Poong Pharmaceutical Co., Ltd.
Registration Date : 2023-02-15
Registration Number : 20230215-209-J-1445
Manufacturer Name : Jari Pharmaceutical Co., Ltd...
Manufacturer Address : No. 18 Zhenhua Road, Lianyungang, China
Registrant Name : Kwangdong Pharmaceutical Co., Ltd.
Registration Date : 2019-11-28
Registration Number : 20191001-209-J-211(1)
Manufacturer Name : Jiangsu Hengrui Pharmaceutic...
Manufacturer Address : Jinqiao Road, Dapu Industrial Park, Economic & Technological Development Zone China
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2019-10-01
Registration Number : 20191001-209-J-211
Manufacturer Name : Jiangsu Hengrui Pharmaceutic...
Manufacturer Address : Jinqiao Road, Dapu Industrial Park, Economic & Technological Development Zone China
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2024-07-25
Registration Number : 20240725-209-J-1669
Manufacturer Name : Natco Pharma Limited
Manufacturer Address : Chemical Division Mekaguda Village, Nandigama Mandal Rangareddy District Telangana, 5...
Registrant Name : Novartis Korea Ltd.
Registration Date : 2021-07-27
Registration Number : 20210727-209-J-1080
Manufacturer Name : Novartis Pharma Schweizerhal...
Manufacturer Address : Rothausstrasse, 4133, Pratteln, Switzerland@Schaffhauserstrasse, 4332 Stein, Switzerl...
Registrant Name : Shin Poong Pharmaceutical Co., Ltd.
Registration Date : 2017-09-13
Registration Number : 20170913-209-J-103
Manufacturer Name : Shin Poong Pharmaceutical Co...
Manufacturer Address : 7 Wonsi-ro, Danwon-gu, Ansan-si, Gyeonggi-do
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2021-11-09
Registration Number : 20211109-209-J-1144
Manufacturer Name : Mexico City SA De CV
Manufacturer Address : Av. San Rafael No. 35, Parque Ind. Lerma, CP 52000, Mpio. Lerma, Mexico
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-809
Start Marketing Date : 2007-11-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69988-0014
Start Marketing Date : 2006-05-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 68554-0039
Start Marketing Date : 1997-07-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57884-0011
Start Marketing Date : 2012-05-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63850-7723
Start Marketing Date : 2016-01-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63850-7701
Start Marketing Date : 2016-01-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1130
Start Marketing Date : 2005-07-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63592-3376
Start Marketing Date : 2018-10-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65096-0116
Start Marketing Date : 2018-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 58623-0099
Start Marketing Date : 2010-08-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
About the Company : Tofigh Daru (TODACO) belongs to the Tamin Pharmaceutical Investment Company, the biggest pharmaceutical holding in Iran. TODACO develops novel APIs in therapeutic categories like A...
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Biesterfeld Spezialchemie GmbH is a part of the Biesterfeld Group. Biesterfeld Spezialchemie GmbH is a pan-European, rapidly growing distributor of products requiring special perfo...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in Ind...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Co-Processed Excipients
Excipient Details : Mannitol is a co-processed excipient with superior compactibility, lower disintegration time, and hygroscopicity.
Application : Fillers, Diluents & Binders
Excipient Details : KoVidone® K25 is used as a low viscosity wet binder in solid dosage forms such as capsules and tablets.
Pharmacopoeia Ref : USP/NF, EP, JP, KP, IP, BP
Technical Specs : NA
Ingredient(s) : Polyvinylpyrrolidone
Grade : Oral
Category : Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Tablet
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 4000
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Lubricants & Glidants, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 4000 is used as a thickener & suspending agent in suspension injections. It is also used as plasticizer, binder, lubricant & solubilizer.
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Global Sales Information
Company :
Letrozole
Drug Cost (USD) : 1,556,773
Year : 2022
Prescribers : 261
Prescriptions : 1236
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 22,556,627
Year : 2022
Prescribers : 189074
Prescriptions : 771460
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 1,950,059
Year : 2021
Prescribers : 316
Prescriptions : 1619
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 22,885,450
Year : 2021
Prescribers : 179561
Prescriptions : 747868
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 20,966,426
Year : 2020
Prescribers : 168860
Prescriptions : 747100
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 2,352,001
Year : 2020
Prescribers : 405
Prescriptions : 2119
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 2,377,228
Year : 2019
Prescribers : 436
Prescriptions : 2267
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 17,884,802
Year : 2019
Prescribers : 160669
Prescriptions : 719744
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 2,708,176
Year : 2018
Prescribers : 507
Prescriptions : 2578
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Letrozole
Drug Cost (USD) : 14,237,952
Year : 2018
Prescribers : 147498
Prescriptions : 694458
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Film-Coated Tablets
Dosage Strength : 2.5mg
Price Per Pack (Euro) : 54.89
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : DISCN
Dosage Form : TABLET;ORAL
Dosage Strength : 2.5MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : DISCN
RX/OTC/DISCN :
Dosage Form : Film-Coated Tablets
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 66.06
Published in :
Country : Italy
RX/OTC/DISCN :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Film-Coated Tablets
Dosage Strength : 2.5mg
Price Per Pack (Euro) : 182.09
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN :
Dosage Form : Film-Coated Tablets
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 66.06
Published in :
Country : Italy
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 51.073
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 159.17
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 51.073
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 159.17
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 51.073
Published in :
Country : Norway
RX/OTC/DISCN :
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2028-06-17
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 8324225
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 209935
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-06-17
Patent Expiration Date : 2029-08-20
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 9416136
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-3998
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-20
Patent Expiration Date : 2036-04-14
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 12064434
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209935
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-04-14
Patent Expiration Date : 2029-12-09
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 8962630
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-3998
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-09
Patent Expiration Date : 2030-05-25
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 8685980
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 209935
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-05-25
Patent Expiration Date : 2031-11-09
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 9868739
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-2505
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-11-09
Patent Expiration Date : 2031-11-09
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 9193732
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 209935
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-11-09
Patent Expiration Date : 2029-12-09
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 8962630
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-3264
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-09
Patent Expiration Date : 2029-08-20
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 9416136
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-3264
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-08-20
Patent Expiration Date : 2031-11-09
LETROZOLE; RIBOCICLIB SUCCINATE
US Patent Number : 9868739
Drug Substance Claim :
Drug Product Claim :
Application Number : 209935
Patent Use Code : U-3264
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-11-09
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Letrozole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Letrozole, including repackagers and relabelers. The FDA regulates Letrozole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Letrozole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Letrozole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Letrozole supplier is an individual or a company that provides Letrozole active pharmaceutical ingredient (API) or Letrozole finished formulations upon request. The Letrozole suppliers may include Letrozole API manufacturers, exporters, distributors and traders.
click here to find a list of Letrozole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Letrozole DMF (Drug Master File) is a document detailing the whole manufacturing process of Letrozole active pharmaceutical ingredient (API) in detail. Different forms of Letrozole DMFs exist exist since differing nations have different regulations, such as Letrozole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Letrozole DMF submitted to regulatory agencies in the US is known as a USDMF. Letrozole USDMF includes data on Letrozole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Letrozole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Letrozole suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Letrozole Drug Master File in Japan (Letrozole JDMF) empowers Letrozole API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Letrozole JDMF during the approval evaluation for pharmaceutical products. At the time of Letrozole JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Letrozole suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Letrozole Drug Master File in Korea (Letrozole KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Letrozole. The MFDS reviews the Letrozole KDMF as part of the drug registration process and uses the information provided in the Letrozole KDMF to evaluate the safety and efficacy of the drug.
After submitting a Letrozole KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Letrozole API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Letrozole suppliers with KDMF on PharmaCompass.
A Letrozole CEP of the European Pharmacopoeia monograph is often referred to as a Letrozole Certificate of Suitability (COS). The purpose of a Letrozole CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Letrozole EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Letrozole to their clients by showing that a Letrozole CEP has been issued for it. The manufacturer submits a Letrozole CEP (COS) as part of the market authorization procedure, and it takes on the role of a Letrozole CEP holder for the record. Additionally, the data presented in the Letrozole CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Letrozole DMF.
A Letrozole CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Letrozole CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Letrozole suppliers with CEP (COS) on PharmaCompass.
A Letrozole written confirmation (Letrozole WC) is an official document issued by a regulatory agency to a Letrozole manufacturer, verifying that the manufacturing facility of a Letrozole active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Letrozole APIs or Letrozole finished pharmaceutical products to another nation, regulatory agencies frequently require a Letrozole WC (written confirmation) as part of the regulatory process.
click here to find a list of Letrozole suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Letrozole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Letrozole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Letrozole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Letrozole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Letrozole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Letrozole suppliers with NDC on PharmaCompass.
Letrozole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Letrozole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Letrozole GMP manufacturer or Letrozole GMP API supplier for your needs.
A Letrozole CoA (Certificate of Analysis) is a formal document that attests to Letrozole's compliance with Letrozole specifications and serves as a tool for batch-level quality control.
Letrozole CoA mostly includes findings from lab analyses of a specific batch. For each Letrozole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Letrozole may be tested according to a variety of international standards, such as European Pharmacopoeia (Letrozole EP), Letrozole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Letrozole USP).
LOOKING FOR A SUPPLIER?